Chapman Rowan E sold $37K of NTRA

Chapman Rowan E sold 135 shares of Natera, Inc. (NTRA) at $274.82 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Rowan E
Published Jul 18, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 18, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

A director’s small open-market sale under a 10b5-1 plan is typically treated as low-signal for fundamentals, but it can be used for monitoring insider activity trends.

02

Market read

Traders may log this as routine insider activity; it is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article provides only the sale details and not total insider holdings changes beyond the post-transaction share count, limiting inference about broader insider sentiment.

Relevance 2/10Novelty 3/10Timing: after-hours/next-session context from a newly filed SEC Form 4 (filed 2026-07-17)

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Chapman Rowan E filed a Form 4 open-market sale of 135 shares at $274.82 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an open-market sale by a director, explicitly under a pre-arranged Rule 10b5-1 plan, and the disclosed value ($37.1K) is small relative to typical company market impact.

Market effects

Minimal. Routine insider selling under 10b5-1 does not materially change the diagnostics/oncology read-through.

None indicated.

None indicated.

Counterpoint

Even planned sales can coincide with internal views on near-term risk, so some traders may still watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Chapman Rowan E

    Director who sold 135 shares at $274.82 per share under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.